Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013241 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
A Phase 2 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
NCT06013241: Completed Phase 2 study, sponsored by Insmed Incorporated.
NCT06013241 is a Phase 2 study that has completed, run by Insmed Incorporated. The registered enrollment target is 288 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (117% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06013241, a Phase 2 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Interventions
- DRUG Placebo
- DRUG Mometasone furoate nasal spray (MFNS)
- DRUG Brensocatib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 2 |
What the finished NCT06013241 record still lists
NCT06013241 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (117% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06013241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06013241 about?
NCT06013241 is a clinical study titled "A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)". The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
What is the current status of trial NCT06013241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2023-10-30. Estimated completion is 2025-10-30.
What interventions are being tested in trial NCT06013241?
The interventions under investigation include: Placebo (DRUG), Mometasone furoate nasal spray (MFNS) (DRUG), Brensocatib (DRUG).
Who is sponsoring clinical trial NCT06013241?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06013241's enrollment target sits among peer trials
288 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI